Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 11 04 2021
accepted: 20 09 2021
entrez: 25 10 2021
pubmed: 26 10 2021
medline: 3 11 2021
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, China, and then rapidly spread causing an unprecedented pandemic. A robust serological assay is needed to evaluate vaccine candidates and better understand the epidemiology of coronavirus disease (COVID-19). We used the full-length spike (S) protein of SARS-CoV-2 for the development of qualitative and quantitative IgG and IgA anti-S enzyme linked immunosorbent assays (ELISA). A total of 320 sera used for assay development were comprised of pandemic sera from SARS-CoV-2 infected adults (n=51) and pre-pandemic sera (n=269) including sera from endemic human coronavirus infected adults. Reverse cumulative curves and diagnostic test statistics were evaluated to define the optimal serum dilution and OD cutoff value for IgG anti-S and IgA anti-S ELISAs. The IgG and IgA anti-S, and three functional antibodies (ACE-2 receptor blocking antibody, lentipseudovirus-S neutralizing antibody, and SARS-CoV-2 neutralizing antibody) were measured using additional SARS-CoV-2 PCR positive sera (n=76) and surveillance sera (n=25). Lastly, the IgG and IgA anti-S levels were compared in different demographic groups. The optimal serum dilution for the qualitative IgG anti-S ELISA was at 1:1024 yielding a 99.6% specificity, 92.2% sensitivity, 92.9% positive predictive value (PPV), and 99.6% negative predictive value (NPV) at a SARS-CoV-2 seroprevalence of 5%. The optimal serum dilution for the qualitative IgA anti-S ELISA was at 1:128 yielding a 98.9% specificity, 76.5% sensitivity, 78.3% PPV, and 98.8% NPV at the same seroprevalence. Significant correlations were demonstrated between the IgG and IgA (r=0.833 for concentrations, r=0.840 for titers) as well as between IgG and three functional antibodies (r=0.811-0.924 for concentrations, r=0.795-0.917 for titers). The IgG and IgA anti-S levels were significantly higher in males than females (p<0.05), and in adults with moderate/severe symptoms than in adults with mild/moderate symptoms (p<0.001). We developed a highly specific and sensitive IgG anti-S ELISA assay to SARS-CoV-2 using full length S protein. The IgG anti-S antibody level was strongly associated with IgA and functional antibody levels in adults with SARS-CoV-2 infection. Gender and disease severity, rather than age, play an important role in antibody levels.

Sections du résumé

Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, China, and then rapidly spread causing an unprecedented pandemic. A robust serological assay is needed to evaluate vaccine candidates and better understand the epidemiology of coronavirus disease (COVID-19).
Methods
We used the full-length spike (S) protein of SARS-CoV-2 for the development of qualitative and quantitative IgG and IgA anti-S enzyme linked immunosorbent assays (ELISA). A total of 320 sera used for assay development were comprised of pandemic sera from SARS-CoV-2 infected adults (n=51) and pre-pandemic sera (n=269) including sera from endemic human coronavirus infected adults. Reverse cumulative curves and diagnostic test statistics were evaluated to define the optimal serum dilution and OD cutoff value for IgG anti-S and IgA anti-S ELISAs. The IgG and IgA anti-S, and three functional antibodies (ACE-2 receptor blocking antibody, lentipseudovirus-S neutralizing antibody, and SARS-CoV-2 neutralizing antibody) were measured using additional SARS-CoV-2 PCR positive sera (n=76) and surveillance sera (n=25). Lastly, the IgG and IgA anti-S levels were compared in different demographic groups.
Results
The optimal serum dilution for the qualitative IgG anti-S ELISA was at 1:1024 yielding a 99.6% specificity, 92.2% sensitivity, 92.9% positive predictive value (PPV), and 99.6% negative predictive value (NPV) at a SARS-CoV-2 seroprevalence of 5%. The optimal serum dilution for the qualitative IgA anti-S ELISA was at 1:128 yielding a 98.9% specificity, 76.5% sensitivity, 78.3% PPV, and 98.8% NPV at the same seroprevalence. Significant correlations were demonstrated between the IgG and IgA (r=0.833 for concentrations, r=0.840 for titers) as well as between IgG and three functional antibodies (r=0.811-0.924 for concentrations, r=0.795-0.917 for titers). The IgG and IgA anti-S levels were significantly higher in males than females (p<0.05), and in adults with moderate/severe symptoms than in adults with mild/moderate symptoms (p<0.001).
Conclusion
We developed a highly specific and sensitive IgG anti-S ELISA assay to SARS-CoV-2 using full length S protein. The IgG anti-S antibody level was strongly associated with IgA and functional antibody levels in adults with SARS-CoV-2 infection. Gender and disease severity, rather than age, play an important role in antibody levels.

Identifiants

pubmed: 34691016
doi: 10.3389/fimmu.2021.693462
pmc: PMC8531527
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin A 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

693462

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI161943
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM056929
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM069234
Pays : United States

Informations de copyright

Copyright © 2021 Ye, Angelo, Nicholson, Iwuchukwu, Cabral de Rezende, Rajan, Aideyan, McBride, Bond, Santarcangelo, Rayford, Ferlic-Stark, Fragoso, Momin, Liu, Truong, Lopez, Conner, Rice, Kimata, Avadhanula and Piedra.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513859
Heliyon. 2020 May;6(5):e04063
pubmed: 32462098
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Immunol Invest. 2020 Sep 18;:1-13
pubmed: 32945214
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
J Clin Med. 2020 Jul 17;9(7):
pubmed: 32708872
J Clin Virol. 2020 Aug;129:104512
pubmed: 32563180
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
J Clin Virol. 2020 Sep;130:104542
pubmed: 32707511
J Clin Virol. 2018 Apr;101:52-56
pubmed: 29427907
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Clin Virol. 2020 Aug;129:104511
pubmed: 32593133
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol. 1995 Nov;69(11):6705-11
pubmed: 7474080
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
J Clin Microbiol. 1998 Feb;36(2):539-42
pubmed: 9466772
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Virology. 1995 Feb 1;206(2):935-44
pubmed: 7531918
Int J Environ Res Public Health. 2020 Dec 15;17(24):
pubmed: 33334073
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 32958614
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Virology. 2020 Dec;551:26-35
pubmed: 33011520
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
PLoS One. 2020 Oct 9;15(10):e0240502
pubmed: 33035234

Auteurs

Xunyan Ye (X)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Laura S Angelo (LS)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Erin G Nicholson (EG)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Obinna P Iwuchukwu (OP)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Wanderson Cabral de Rezende (W)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Department of Pharmacology, Baylor College of Medicine, Houston, TX, United States.

Anubama Rajan (A)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Letisha O Aideyan (LO)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Trevor J McBride (TJ)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Nanette Bond (N)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Patricia Santarcangelo (P)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Yolanda J Rayford (YJ)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Laura Ferlic-Stark (L)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Sonia Fragoso (S)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Zoha Momin (Z)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Hongbing Liu (H)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Khanghy Truong (K)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Brianna Lopez (B)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Margaret E Conner (ME)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Andrew P Rice (AP)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Jason T Kimata (JT)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Vasanthi Avadhanula (V)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.

Pedro A Piedra (PA)

Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Department of Pharmacology, Baylor College of Medicine, Houston, TX, United States.
Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH